HUTCHMED (China) (HMDCF) Non Operating Income (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Non Operating Income came in at $3.0 million in Q2 2021, up 624.94% year-over-year from $413000.0 in Q2 2020, and up 921.84% quarter-over-quarter from $293000.0 in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Non Operating Income (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Non Operating Income for 4 consecutive years, with $3.0 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Non Operating Income rose 624.94% year-over-year to $3.0 million in Q2 2021; TTM through Jun 2021 was $4.9 million, a 54.37% increase from a year earlier, with the FY2025 full-year figure at $61.0 million, up 43.09% from the prior year.
- Non Operating Income was $3.0 million for Q2 2021 at HUTCHMED (China), up from $293000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $3.0 million in Q2 2021 and troughed at -$31000.0 in Q4 2019.
- A 4-year average of $1.3 million and a median of $1.2 million in 2018 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income tumbled 102.8% in 2019 and soared 624.94% in 2021, its largest moves.
- Over 4 years, Non Operating Income stood at $1.1 million in 2018, then plunged by 102.8% to -$31000.0 in 2019, then jumped by 1432.26% to $413000.0 in 2020, then soared by 624.94% to $3.0 million in 2021.
- The last three Non Operating Income figures came in at $3.0 million (Q2 2021), $293000.0 (Q1 2021), and $413000.0 (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.93 Bn | 198.94 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 181.03 Bn | 177.85 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.73 Bn | 124.87 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.26 Bn | 74.27 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.30 Bn | 56.11 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.88 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.22 Bn | 29.94 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 2.99 Mn |
| Mar 31, 2021 | 293,000.00 |
| Jun 30, 2020 | 413,000.00 |
| Mar 31, 2020 | 1.17 Mn |
| Dec 31, 2019 | -31,000.00 |
| Sep 30, 2019 | 1.60 Mn |
| Jun 30, 2019 | 2.57 Mn |
| Mar 31, 2019 | 1.14 Mn |
| Dec 31, 2018 | 1.11 Mn |
| Sep 30, 2018 | 1.69 Mn |
| Jun 30, 2018 | 2.04 Mn |
| Mar 31, 2018 | 1.15 Mn |